{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:30:53Z","timestamp":1777728653555,"version":"3.51.4"},"reference-count":32,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2024,4,25]]},"DOI":"10.1272\/jnms.jnms.2024_91-214","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:12:09Z","timestamp":1716243129000},"page":"233-240","source":"Crossref","is-referenced-by-count":3,"title":["Usefulness of Gabapentin as an Alternative\/Adjunct Therapy for Delirium: A Retrospective Observational Study"],"prefix":"10.1272","volume":"91","author":[{"given":"Kakusho Chigusa","family":"Nakajima-Ohyama","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Nippon Medical School Musashi Kosugi Hospital"},{"name":"Department of Neuropsychiatry, Ikeda Municipal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshie","family":"Shizusawa","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Ikeda Municipal Hospital"},{"name":"Department of Palliative Medicine, Osaka Gyoumeikan Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Nippon Medical School Musashi Kosugi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Nippon Medical School Musashi Kosugi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Tanimukai","sequence":"additional","affiliation":[{"name":"School of Human Health Sciences, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kishi T, Hirota T, Matsunaga S, Iwata N. Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2016 Jul;87 (7):767-74.","DOI":"10.1136\/jnnp-2015-311049"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016 Apr;64 (4):705-14.","DOI":"10.1111\/jgs.14076"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19;294 (15):1934-43.","DOI":"10.1001\/jama.294.15.1934"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ebersbach G, Ip CW, Klebe S, et al. Management of delirium in Parkinson&apos;s disease. J Neural Transm (Vienna). 2019 Jul;126 (7):905-12.","DOI":"10.1007\/s00702-019-01980-7"},{"key":"5","unstructured":"5. [Japanese Society of General Hospital Psychiatry Delirium Guideline Revision Group]. [Clinical guideline for delirium: treatment guidelines for delirium, second edition: Japanese Society of General Hospital Psychiatry Treatment Guideline 1]. 2nd ed. Tokyo: Seiwa Shoten; 2015. Japanese."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 Sep;33 (9):1582-8.","DOI":"10.1111\/j.1530-0277.2009.00986.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006 Jan-Feb;15 (1):76-84.","DOI":"10.1080\/10550490500419110"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Leung JG, Rakocevic DB, Allen ND, et al. Use of a gabapentin protocol for the management of alcohol withdrawal: a preliminary experience expanding from the consultation-liaison psychiatry service. Psychosomatics. 2018 Sep-Oct;59 (5):496-505.","DOI":"10.1016\/j.psym.2018.03.002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bates RE, Leung JG, Morgan RJ 3rd, Fischer KM, Philbrick KL, Kung S. Retrospective analysis of gabapentin for alcohol withdrawal in the hospital setting: the Mayo Clinic experience. Mayo Clin Proc Innov Qual Outcomes. 2020 Aug 19;4 (5):542-9.","DOI":"10.1016\/j.mayocpiqo.2020.06.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pinto Filho WA, Silveira LHJ, Vale ML, Fernandes CR, Gomes JA. Gabapentin in improvement of procedural sedation and analgesia in oncologic pediatric patients: a clinical trial. Anesth Pain Med. 2019 Oct 28;9 (5):e91197.","DOI":"10.5812\/aapm.91197"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Badawy AA, Kasem SA, Rashwan D, et al. The role of gabapentin oral solution in decreasing desflurane associated emergence agitation and delirium in children after stabismus surgery, a prospective randomized double-blind study. BMC Anesthesiol. 2018 Jun 20;18 (1):73.","DOI":"10.1186\/s12871-018-0533-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Leung JM, Sands LP, Rico M, et al. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology. 2006 Oct 10;67 (7):1251-3.","DOI":"10.1212\/01.wnl.0000233831.87781.a9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Leung JM, Sands LP, Chen N, et al. Perioperative gabapentin does not reduce postoperative delirium in older surgical patients: a randomized clinical trial. Anesthesiology. 2017 Oct;127 (4):633-44.","DOI":"10.1097\/ALN.0000000000001804"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gupta A, Joshi P, Bhattacharya G, et al. Is there evidence for using anticonvulsants in the prevention and\/or treatment of delirium among older adults? Int Psychogeriatr. 2022 Oct;34 (10):889-903.","DOI":"10.1017\/S1041610221000235"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Abe H, Sumitani M, Matsui H, et al. Anesth Analg. Gabapentinoid use is associated with reduced occurrence of hyperactive delirium in older cancer patients undergoing chemotherapy: a nationwide retrospective cohort study in Japan. Anesth Analg. 2022 Aug 1;135 (2):362-9.","DOI":"10.1213\/ANE.0000000000006093"},{"key":"16","unstructured":"16. Nakajima-Ohyama KC, Okada A, Hayano E, et al. Efficacy and safety of gabapentin for delirium in Parkinson&apos;s disease: a case series. Jpn J Gen Hosp Psychiatry. 2019;31 (2):207-15."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Supasitthumrong T, Bolea-Alamanac BM, Amser S, Woo VL, Abdool PS, Davies SJC. Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report. Br J Clin Pharmacol. 2019 Apr;85 (4):690-703.","DOI":"10.1111\/bcp.13844"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bergeron N, Dubois MJ, Dumont M, Dial S, Strobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001 May;27 (5):859-64.","DOI":"10.1007\/s001340100909"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Koga Y, Murata H, Yamase H. Validity and reliability of the Japanese version of Intensive Care Delirium Screening Checklist (ICDSC). Yamaguchi Med J. 2014 May 1;63 (2):103-11 Japanese.","DOI":"10.2342\/ymj.63.103"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant. 2013 Mar;48 (3):452-8.","DOI":"10.1038\/bmt.2012.244"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Inouye SK. Predisposing and precipitating factors for delirium in hospitalized older patients. Dement Geriatr Cogn Disord. 1999 Sep-Oct;10 (5):393-400.","DOI":"10.1159\/000017177"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Maldonado JR. Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry. 2018 Nov;33 (11):1428-57.","DOI":"10.1002\/gps.4823"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Honmou O, Oyelede AA, Kocsis JD. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res. 1995 Sep 18;692 (1-2):273-7.","DOI":"10.1016\/0006-8993(95)00634-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Honmou O, Kocsis JD, Richerson GB. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res. 1995 Mar;20 (3):193-202.","DOI":"10.1016\/0920-1211(94)00076-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996 Mar 8;271 (10):5768-76.","DOI":"10.1074\/jbc.271.10.5768"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Loscher W, Honack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett. 1991 Jul 22;128 (2):150-4.","DOI":"10.1016\/0304-3940(91)90249-S"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Foldvary-Schaefer N, De Leon, Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002 Dec;43 (12):1493-7.","DOI":"10.1046\/j.1528-1157.2002.21002.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 2016 Mar;50 (3):229-33.","DOI":"10.1177\/1060028015620800"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Bonnet U, Richter EL, Isbruch K, Scherbaum N. On the addictive power of gabapentinoids: a mini-review. Psychiatr Danub. 2018 Jun;30 (2):142-9.","DOI":"10.24869\/psyd.2018.142"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017 Dec;27 (12):1185-215.","DOI":"10.1016\/j.euroneuro.2017.08.430"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ahmed S, Stanciu CN, Kotapati PV, et al. Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review. Prim Care Companion CNS Disord. 2019 Aug 22;21 (4):19r02465.","DOI":"10.4088\/PCC.19r02465"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Desai A, Kherallah Y, Szabo C, Marawar R. Gabapentin or pregabalin induced myoclonus: a case series and literature review. J Clin Neurosci. 2019 Mar;61:225-34.","DOI":"10.1016\/j.jocn.2018.09.019"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/91\/2\/91_JNMS.2024_91-214\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T04:06:32Z","timestamp":1716609992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/91\/2\/91_JNMS.2024_91-214\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2024_91-214","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"article-number":"JNMS.2024_91-214"}}